OncLive 9 CLL Videos - Optimizing the Treatment of CLL With Novel Therapies and more Take-home messages from ASH 2021

[lankisterguy]

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

onclive.com/clinical/cll

-

Optimizing the Treatment of CLL With Novel Therapies March 14th 2022

onclive.com/view/optimizing...

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

-

CAR T-Cell Therapies in CLL March 14th 2022

onclive.com/view/car-t-cell...

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

-

PI3K Inhibitors for CLL March 7th 2022

onclive.com/view/pi3k-inhib...

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

-

Noncovalent BTK Inhibitors in CLL March 7th 2022

onclive.com/view/noncovalen...

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

-

FDA Extends PDUFA Date for BLA/sNDA of Ublituximab Plus Umbralisib in CLL/SLL March 3rd 2022

onclive.com/view/fda-extend...

The FDA has extended the Prescription Drug User Fee Act goal date for the biologics license application and supplemental new drug application seeking the approval of ublituximab plus umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Burger on the Current Landscape of CAR T-Cell Therapy in CLL February 28th 2022

onclive.com/view/dr-burger-...

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

-

Dr. Oh on the Evolving Treatment Landscape in CLL February 24th 2022

onclive.com/view/dr-oh-on-t...

Stephen Oh, MD, PhD, discuses the evolving treatment landscape of chronic lymphocytic leukemia.

-

Dr. Kahl on the Potential of Zanubrutinib in the Frontline Treatment of CLL February 24th 2022

onclive.com/view/dr-kahl-on...

Brad S. Kahl, MD, discusses the potential for zanubrutinib in the frontline treatment of chronic lymphocytic leukemia.

-

Zanubrutinib Applications for CLL and MZL Accepted for Review in Europe February 23rd 2022

onclive.com/view/zanubrutin...

The European Medicines Agency has accepted for review 2 new indication applications for zanubrutinib as a therapeutic option for patients with chronic lymphocytic leukemia and for those with marginal zone lymphoma.

-

Len

[Name-1]

Thank You Len!😀

[Sushibruno]

All this did was scare me and make me cry. Cll is the devil!!

[Justasheet1 in reply to Sushibruno]

Lydia,

Imagine a world without these great treatments available. Now that’s a reason to be scared.

That was the case only a few years ago. Being untreated with these available and having a CLL expert on board as you do, you need not worry.

Go do something fun today.

Jeff

[Sushibruno in reply to Justasheet1]

Jeff things get to me very easily that's why I react the way I do. I shouldn't be reading because it takes me to the wrong place. When I listened to this I cried and threw my phone cried on my husband's shoulder I can't take that I have this. But I understand and am grateful that there are good treatment out there. With my appt. Coming up it exacerbates my feelings. But I appreciate your response to me. I have to live and move on🙂.

[Sushibruno in reply to Justasheet1]

Thanks Jeff

[Justasheet1 in reply to Sushibruno]

You’re welcome Lydia 😉

[Smakwater]

Thanks Len, now I have homework.

But, I love homework.

JM